3D Stem Cell Culture for Off-the-Shelf Non-Alloreactive T Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current engineered T cell therapies rely on autologous peripheral blood T cells, which are labor and cost-intensive, and have scalability issues, and are ineffective in patients with lymphopenia or impaired T cells, leading to a need for non-alloreactive, off-the-shelf therapies.
Innovation Solution
A novel three-dimensional cell culture system using serum-free medium to produce non-alloreactive T cells from embryonic stem cells or progenitor cells, expressing an exogenous TCR and/or CAR, with a culture composition that includes specific Notch ligands and vitamins, cytokines, and a defined extracellular matrix.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If autologous peripheral blood T cells are used for engineered T cell therapy, then patient-specific treatment is achieved, but labor and cost intensity increases significantly
Solution Approach 1:
The patent uses patient-specific MHC molecules and antigens to generate T cell receptors (TCRs) that can be copied and expressed in allogeneic T cells. This creates 'off-the-shelf' therapies that replicate the patient-specific immune response without requiring patient-specific T cell collection and engineering, thereby reducing labor and cost while maintaining treatment efficacy
Solution Approach 2:
The invention separates the patient-specific elements (MHC-TCR complexes) from the T cell production process. Patient-specific MHC molecules and antigens are used to generate TCR sequences in vitro, which are then introduced into allogeneic T cells. This segmentation allows patient-specificity to be achieved through molecular copying rather than whole-cell engineering
2Reliability
If autologous T cells are used for engineered T cell therapy, then immune compatibility is improved, but scalability and productivity decrease
Solution Approach 1:
Patient-specific TCR sequences are copied and introduced into allogeneic T cells, enabling scalable production of patient-matched therapies. The allogeneic T cells serve as a renewable platform that can be manufactured at scale while expressing patient-specific antigen recognition capabilities
Solution Approach 2:
The patent creates a universal allogeneic T cell platform that can be engineered to express different patient-specific TCRs. This multi-functional platform allows the same base cell product to be adapted for multiple patients, greatly enhancing scalability while maintaining patient-specific immune compatibility
3Reliability
If patient's own T cells are used, then treatment is effective for the patient, but it cannot be applied to patients with lymphopenia or impaired T cells
Solution Approach 1:
The patent generates TCR sequences from patient-specific MHC-antigen interactions in vitro, then introduces these into healthy allogeneic T cells. This allows patients with lymphopenia or impaired T cells to receive functional T cells that have been engineered to recognize their specific antigens, expanding treatment eligibility while maintaining effectiveness
Solution Approach 2:
Instead of taking T cells from the patient and engineering them, the invention inverts the process by engineering T cells externally and introducing them into the patient. This reversal allows the use of healthy donor T cells that can be engineered to patient-specific targets, making treatment accessible to patients who cannot provide adequate T cells
4Productivity
If allogeneic T cells are used, then scalability is improved, but graft-versus-host disease risk increases
Solution Approach 1:
The patent engineers T cells to express patient-specific TCRs that recognize only the patient's own MHC-antigen complexes. This localized specificity ensures that allogeneic T cells will not recognize and attack the patient's healthy tissues, eliminating GVHD risk while maintaining the scalability benefits of using allogeneic donor cells
Data Source
AI summary
Methods and composition for production of T cells are provided. Also provided are therapeutic methods using engineered T cells. For example, in certain aspects methods include preparing three dimensional cell culture compositions comprising stroma cells and hematopoietic stem or progenitor cells in a serum-free medium for producing T cells.